Biomedical Diagnostics (BMD) becomes Theradiag and moves into theranostics
Theradiag, the new name for BMD, is the combination of "theranostics" and "diagnostics", the company´s two areas of activity. This name change reflects its new strategic direction towards developing and marketing theranostic tests for biotherapies.
Theranostics is an emerging branch of in vitro diagnostics that provides information which can lead to treatments that are more tailored to individual patients. Theranostic testing is combined with targeted biotherapy to predict or assess a patient´s response by measuring one or more biomarkers.
"The company´s name change relates to our new strategy of implementing theranostics. Today, 70% of all new drugs are biotherapies, and determining precisely how a patient will respond to a treatment is crucial. Theranostic tests are the best tools we have to monitor these biotherapies. The development of personalized medicine will allow us to provide better care for patients, while saving money for actors in the pharmaceutical industry," states Michel Finance, Theradiag´s CEO.
New position in the theranostics market
Using its expertise in IVD and autoimmunity, from development phase to commercialization through regulation affair process, Theradiag will now be focusing its development strategy on theranostic tests to monitor biotherapies. In 2011, Theradiag received a CE mark and marketed a new product line called Lisa Tracker, which improves monitoring for patients receiving anti-TNF treatment. Other new theranostic products are currently in development.
A company with strong global positioning in the in vitro diagnostics (IVD) market
With over 25 years of experience in in vitro diagnostics and autoimmune diseases, Theradiag is a well-known developer, manufacturer and marketer of high-quality, innovative IVD products. As an industry world leader the company offers a complete line of products for diagnosis of autoimmune disorders, allergies and infectious diseases. Theradiag has also developed the most complete panel of IVD products for autoimmune disorders using Luminex® multiplex technology. In the coming years, Theradiag´s IVD activity will be concentrated on products developed internally and marketed worldwide, primarily in autoimmunity.
About Theradiag
Theradiag has over 25 years of experience in the autoimmune disorder diagnostics market. It is currently moving into the theranostic testing market to improve biotherapy monitoring, including for autoimmune diseases. The company is based in Marne la Vallée (France) and has approximately 50 employees.
For more information about the company, visit our website: www.theradiag.com